Bristol-Myers Squibb
Business & Industry
- Bayer acquires HiDoc Technologies and Cara Care® app for irritable bowel syndrome
- First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO Guidelines
- Pfizer announces new Chief Scientific Officer and President, Research & Development
- AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
- Bayer Foundation announces Science Awards winners of 2024
Research & Development
- Nano drug delivery system heralds safer era for drug development
- New drug shows promise against Duchenne muscular dystrophy
- Breakthrough of the Year: A drug that prevents HIV infection, providing six months of protection per shot
- Paracetamol may not be as safe as perceived in older people, according to a new study
- New gene therapy reverses heart failure in large animal model
- Genetic code deploys cancer mafia, new targeted drug gives them an offer they can't refuse
- A new method for efficient synthesis of anti-cancer drugs
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy